139 related articles for article (PubMed ID: 8132702)
1. Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.
Mohler JL; Williams BT; Thompson IM; Marshall ME
J Cancer Res Clin Oncol; 1994; 120 Suppl():S35-8. PubMed ID: 8132702
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma.
Mohler JL; Gomella LG; Crawford ED; Glode LM; Zippe CD; Fair WR; Marshall ME
Prostate; 1992; 20(2):123-31. PubMed ID: 1549551
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hormone-refractory stage D carcinoma of prostate with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.
Marshall ME; Butler K; Hermansen D
Prostate; 1990; 17(2):95-9. PubMed ID: 2399194
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies.
Marshall ME; Butler K; Fried A
Mol Biother; 1991 Sep; 3(3):170-8. PubMed ID: 1768368
[TBL] [Abstract][Full Text] [Related]
5. An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin.
Marshall ME; Mohler JL; Edmonds K; Williams B; Butler K; Ryles M; Weiss L; Urban D; Bueschen A; Markiewicz M
J Cancer Res Clin Oncol; 1994; 120 Suppl():S39-42. PubMed ID: 8132703
[TBL] [Abstract][Full Text] [Related]
6. 2nd Proceedings of The International Society of Coumarin Investigators (ISCI). 1,2-Benzopyrone (Coumarin): update on mechanisms of action - Treatment of renal cell carcinoma and prostate cancer - Prevention of melanoma recurrence. Hamburg, Germany, 9 March 1994.
J Cancer Res Clin Oncol; 1994; 120 Suppl():S1-42. PubMed ID: 7907598
[No Abstract] [Full Text] [Related]
7. Evaluation of the antitumour activity of coumarin in prostate cancer models.
Maucher A; Kager M; von Angerer E
J Cancer Res Clin Oncol; 1993; 119(3):150-4. PubMed ID: 8418087
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of coumarin in prostate and mammary cancer models.
von Angerer E; Kager M; Maucher A
J Cancer Res Clin Oncol; 1994; 120 Suppl():S14-6. PubMed ID: 8132695
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.
Marshall ME; Mendelsohn L; Butler K; Riley L; Cantrell J; Wiseman C; Taylor R; Macdonald JS
J Clin Oncol; 1987 Jun; 5(6):862-6. PubMed ID: 3585442
[TBL] [Abstract][Full Text] [Related]
10. Effects of coumarin (1,2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies.
Marshall ME; Riley LK; Rhoades J; Eichhorn T; Jennings CD; Cibull M; Thompson J
J Biol Response Mod; 1989 Feb; 8(1):62-9. PubMed ID: 2921610
[TBL] [Abstract][Full Text] [Related]
11. Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation.
Ahlering TE; Skarecky DW; McLaren CE; Weinberg AC
Cancer; 2002 Mar; 94(6):1648-53. PubMed ID: 11920524
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Oesterling JE; Chan DW; Epstein JI; Kimball AW; Bruzek DJ; Rock RC; Brendler CB; Walsh PC
J Urol; 1988 Apr; 139(4):766-72. PubMed ID: 2451037
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
15. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
16. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery.
Revelo MP; Cookson MS; Chang SS; Shook MF; Smith JA; Shappell SB
J Urol; 2004 Feb; 171(2 Pt 1):646-51. PubMed ID: 14713778
[TBL] [Abstract][Full Text] [Related]
17. Risk of prostate carcinoma death in patients with lymph node metastasis.
Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
[TBL] [Abstract][Full Text] [Related]
18. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
[TBL] [Abstract][Full Text] [Related]
20. [Early results following radical prostatectomy in patients with capsule invasion, seminal vesicle infiltration and micrometastases].
Terhorst B; Friedrichs R
Urologe A; 1990 Mar; 29(2):91-5. PubMed ID: 2330669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
